Patents by Inventor Ashok Bhandari

Ashok Bhandari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL a4B7 PEPTIDE DIMER ANTAGONISTS
    Publication number: 20160368966
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: January 19, 2016
    Publication date: December 22, 2016
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • A4B7 peptide monomer and dimer antagonists
    Patent number: 9518091
    Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: December 13, 2016
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
  • NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
    Publication number: 20160159862
    Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
    Type: Application
    Filed: February 17, 2016
    Publication date: June 9, 2016
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
  • NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
    Publication number: 20160152664
    Abstract: The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against ?4?1 binding, and have high stability under gastrointestinal conditions.
    Type: Application
    Filed: October 1, 2015
    Publication date: June 2, 2016
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
  • ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES
    Publication number: 20160145306
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease.
    Type: Application
    Filed: July 15, 2015
    Publication date: May 26, 2016
    Inventors: Gregory Thomas Bourne, Ashok Bhandari, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • ?4?7 peptide dimer antagonists
    Patent number: 9273093
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: March 1, 2016
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
    Publication number: 20160031944
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Application
    Filed: May 15, 2015
    Publication date: February 4, 2016
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis
  • NOVEL A4B7 PEPTIDE DIMER ANTAGONISTS
    Publication number: 20140294901
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 2, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • NOVEL A4B7 PEPTIDE ANTAGONISTS
    Publication number: 20140294902
    Abstract: The invention relates to disulfide-rich peptide molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 2, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • NOVEL a4B7 PEPTIDE DIMER ANTAGONISTS
    Publication number: 20140193465
    Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.
    Type: Application
    Filed: October 10, 2013
    Publication date: July 10, 2014
    Applicant: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20130012685
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: July 3, 2012
    Publication date: January 10, 2013
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules
    Publication number: 20120165275
    Abstract: Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis.
    Type: Application
    Filed: December 21, 2011
    Publication date: June 28, 2012
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Anjan Chakrabarti, Brian T. Frederick, Yijun Pan, Yaohua S. Dong, Ashok Bhandari
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20120157660
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: August 18, 2010
    Publication date: June 21, 2012
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
  • Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
    Patent number: 8106154
    Abstract: Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: January 31, 2012
    Assignee: Affymax, Inc.
    Inventors: Christopher P. Holmes, Anjan Chakrabarti, Brian T. Frederick, Yijun Pan, Yaohua S. Dong, Ashok Bhandari
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20110282029
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: December 10, 2010
    Publication date: November 17, 2011
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • COMPOUNDS AND PEPTIDES THAT BIND THE TRAIL RECEPTOR
    Publication number: 20090131317
    Abstract: The present invention relates to peptides and compounds that bind to a TRAIL receptor or otherwise act as a TRAIL receptor agonist, as well as methods of treating human diseases using the same. In addition, methods of synthesizing the peptides and compounds described herein are provided by the present invention.
    Type: Application
    Filed: June 23, 2008
    Publication date: May 21, 2009
    Applicant: AFFYMAX, INC.
    Inventors: Yvonne M. Angell, Ashok Bhandari, Jennifer Green, Peter J. Schatz, Christopher P. Holmes
  • NITROGEN-BASED LINKERS FOR ATTACHING MODIFYING GROUPS TO POLYPEPTIDES AND OTHER MACROMOLECULES
    Publication number: 20090048147
    Abstract: The present invention relates to a compound comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The linker moiety is between the peptide moiety and the water-soluble polymer moiety. In certain embodiments, the linker moiety has the structure: wherein ?, ?, and ? are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein ?, ?, and ? are each integers whose values are independently selected. In other embodiments the linker moiety has the following structure: wherein ?, ?, ?, and ? are each integers whose values are independently selected. Alternatively, the linker structure may have the following structure: wherein ? and ? are each integers whose values are independently selected.
    Type: Application
    Filed: January 30, 2008
    Publication date: February 19, 2009
    Applicant: Affymax, Inc.
    Inventors: Christopher P. Holmes, Anjan Chakrabarti, Brian T. Frederick, Yijun Pan, Yaohua S. Dong, Ashok Bhandari
  • Novel Peptides that Bind to the Erythropoietin Receptor
    Publication number: 20090005292
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: November 11, 2005
    Publication date: January 1, 2009
    Applicant: AFFYMAX, INC.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, David Tumelty, Guy Lalonde, Palani Balu, Peter J. Schatz, William J. Dower, Anjan Chakrabarti, Yaohua S. Dong, Brian T. Frederick, Nicholas C. Wrighton
  • NOVEL PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR
    Publication number: 20080108564
    Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention further relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.
    Type: Application
    Filed: April 13, 2007
    Publication date: May 8, 2008
    Applicant: Affymax, Inc.
    Inventors: Christopher P. Holmes, Qun Yin, Genet Zemede, Ashok Bhandari, Yaohua S. Dong, David Tumelty, Guy Lalonde, Brian T. Frederick, Anjan Chakrabarti, Palani Balu, Peter J. Schatz, Nicholas C. Wrighton, William J. Dower
  • Condensed heterocyclic compounds as calcitonin agonists
    Patent number: 7189851
    Abstract: The present invention relates to novel fused heterocyclic ring system compounds and methods for their use in the treatment and prevention of diseases or conditions.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: March 13, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Ashok Bhandari, Eric Eugene Boros, David John Cowan, Anthony Louis Handlon, Clifton Earl Hyman, Jeffrey Alan Oplinger, Michael Howard Rabinowitz, Philip Stewart Turnbull